D2 Receptor Occupancy in Conscious Rat Brain is Not Significantly Distinguished With [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-Raclopride

被引:12
作者
Peng, Teng [1 ]
Zysk, John [1 ]
Dorff, Peter [2 ]
Elmore, Charles S. [2 ]
Strom, Peter
Malmquist, Jonas
Ding, Min [1 ]
Tuke, David [1 ]
Werkheiser, Jennifer [1 ]
Widzowski, Dan [1 ]
Mrzljak, Ladislav [1 ]
Maier, Donna [1 ]
机构
[1] AstraZeneca, CNS Discovery, Dept Neurosci, Wilmington, DE 19850 USA
[2] AstraZeneca, CNS Discovery, Dept Chem, Wilmington, DE 19850 USA
关键词
D2; receptor; MNPA; PHNO; raclopride; haloperidol; quinpirole; aripiprazole; in vivo receptor occupancy; in vitro binding; HIGH-AFFINITY STATE; POSITRON-EMISSION-TOMOGRAPHY; NONHUMAN PRIMATE BRAIN; IN-VIVO; ENDOGENOUS DOPAMINE; D-3; RECEPTORS; AGONIST RADIOTRACER; ANTERIOR-PITUITARY; BINDING; PET;
D O I
10.1002/syn.20771
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Positron emission tomography (PET) antagonist ligands such as [C-11]-raclopride are commonly used to study dopamine D2 receptor (D2) binding of antipsychotics It has been suggested that agonist radioligands bind preferentially to the high-affinity state of D2 receptor and may provide a more relevant means of assessing D2 occupancy. The main objective of this study was to determine if D2 receptor occupancy (RO) could be differentiated with agonist and antagonist radioligands in vivo. Agonist radioligands [H-3]-MNPA and [H-3]-(+)-PHNO were synthesized and compared to antagonist [H-3]-raclopride in the in vitro binding and in vivo occupancy studies. In vivo, unanesthetized rats were pretreated with quinpirole (full agonist), aripiprazole (partial agonist), or haloperidol (antagonist) prior to administration of the agonist or antagonist radioligand All three pretreatment compounds showed equivalent dose-dependent D2 receptor occupancy in the rat striatum with each radioligand. The in vivo receptor occupancy results suggested that the binding of quinpirole, aripiprazole, and haloperidol to the high or low affinity state of the D2 receptor could not be differentiated using radiolabeled agonists or antagonists, presumably due to a predominance of high affinity states of the D2 receptor in vivo. This hypothesis was supported in part by the in vitro binding results. Our in vitro results show that [H-3]-MNPA binds to D2S transfected CHO cell membranes at a single high affinity site. Displacement of [H-3]-(+)-PHNO binding by quinpirole and elimination of most [H-3]-(+)-PHNO binding by the guanine nucleotide GppNHp in striatal membranes suggest that the majority of D2 in striatal tissue is G-protein coupled. Together, these findings suggest that D2 agonist radioligands produce in vivo receptor occupancy comparable to [H-3]-raclopride Synapse 64:624-633, 2010. (C) 2010 Wiley-Liss, Inc
引用
收藏
页码:624 / 633
页数:10
相关论文
共 48 条
[1]   Conditioned dopamine release in humans:: A positron emission tomography [11C] raclopride study with amphetamine [J].
Boileau, Isabelle ;
Dagher, Alain ;
Leyton, Marco ;
Welfeld, Krzysztof ;
Booij, Linda ;
Diksic, Mirko ;
Benkelfat, Chawki .
JOURNAL OF NEUROSCIENCE, 2007, 27 (15) :3998-4003
[2]   Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors [J].
Burris, KD ;
Molski, TF ;
Xu, C ;
Ryan, E ;
Tottori, K ;
Kikuchi, T ;
Yocca, FD ;
Molinoff, PB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :381-389
[3]  
Carson W. H., 2000, European Neuropsychopharmacology, V10, pS309
[4]   SUSTAINED-RELEASE (+)-PHNO [MK-458 (HPMC)] IN THE TREATMENT OF PARKINSONS-DISEASE - EVIDENCE FOR TOLERANCE TO A SELECTIVE D2-RECEPTOR AGONIST ADMINISTERED AS A LONG-ACTING FORMULATION [J].
CEDARBAUM, JM ;
CLARK, M ;
TOY, LH ;
GREENPARSONS, A .
MOVEMENT DISORDERS, 1990, 5 (04) :298-303
[5]   Specific binding of [11C]raclopride and N-[3H]propyl-norapomorphine to dopamine receptors in living mouse striatum:: Occupancy by endogenous dopamine and guanosine triphosphate-free G protein [J].
Cumming, P ;
Wong, DF ;
Gillings, N ;
Hilton, J ;
Scheffel, U ;
Gjedde, A .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2002, 22 (05) :596-604
[6]  
DELEAN A, 1982, MOL PHARMACOL, V22, P290
[7]   Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability [J].
DeLeon, A ;
Patel, NC ;
Crismon, ML .
CLINICAL THERAPEUTICS, 2004, 26 (05) :649-666
[8]  
FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71
[9]  
FARDE L, 1987, ARCH GEN PSYCHIAT, V44, P671
[10]   A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey [J].
Finnema, SJ ;
Seneca, N ;
Farde, L ;
Shchukin, E ;
Sóvágó, J ;
Gulyás, B ;
Wikström, HV ;
Innis, RB ;
Neumeyer, JL ;
Halldin, C .
NUCLEAR MEDICINE AND BIOLOGY, 2005, 32 (04) :353-360